Increased Serum MicroRNA-155 Level Associated with Nonresponsiveness to Hepatitis B Vaccine

Xiong, Yuyan; Chen, Shengli; Liu, Linhua; Zhao, Yi; Lin, Weiyan; Ni, Jiajia

doi:10.1128/cvi.00044-13

Cited by 13 publications

(14 citation statements)

References 10 publications

(7 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Agilent array analysis identified differential expression of 19 miRNAs after correction for multiple testing. This finding supports work by others showing vaccination alters serum miRNA expression[19,46]. For example, Xiong et al found that increased serum miRNA-155 at 4 to 6 weeks post hepatitis B vaccination was associated with non-response to the vaccine (defined as anti-HBsAg antibody levels below 10 mIU/ml)[46].…”

Section: Discussionsupporting

confidence: 86%

The effect of H1N1 vaccination on serum miRNA expression in children: A tale of caution for microRNA microarray studies

2019

View full text Add to dashboard Cite

Background MicroRNAs (miRNAs) are a class of small regulatory RNAs around 21–25 nucleotides in length which govern many aspects of immunity including the host innate and adaptive responses to infection. RT-qPCR studies of select microRNAs show that vaccination alters the expression circulating microRNAs but the effect of vaccination on the global microRNA population (i.e. micronome) has never been studied. Aim To describe vaccine associated changes in the expression of microRNAs 21 days after vaccination in children receiving a pandemic influenza (H1N1) vaccination. Method Serum samples were obtained from children aged 6 months to 12 years enrolled in an open label randomised control trial of two pandemic influenza (H1N1) vaccines, in which participants received either ASO3B adjuvanted split virion or a whole virion non-adjuvanted vaccine. MicroRNA expression was profiled in a discovery cohort of participants prior to, and 21 days after vaccination using an Agilent microarray platform. Findings were followed up by RT-qPCR in the original discovery cohort and then in a validation cohort of participants taken from the same study. Results 44 samples from 22 children were assayed in a discovery cohort. The microarray results revealed 19 microRNAs were differentially expressed after vaccination after adjustment for multiple testing. The microarray detected ubiquitous expression of several microRNAs which could not be validated by RT-qPCR, many of which have little evidence of existence in publicly available RNA sequencing data. Real time PCR (RT-qPCR) confirmed downregulation of miR-142-3p in the discovery cohort. These findings were not replicated in the subsequent validation cohort (n = 22). Conclusion This study is the first study to profile microRNA expression after vaccination. An important feature of this study is many of the differentially expressed microRNAs could not be detected and validated by RT-qPCR. This study highlights the care that should be taken when interpreting omics biomarker discovery, highlighting the need for supplementary methods to validate microRNA microarray findings, and emphasises the importance of validation cohorts. Data from similar studies which do not meet these requirements should be interpreted with caution.

show abstract

Section: Discussionsupporting

confidence: 86%

The effect of H1N1 vaccination on serum miRNA expression in children: A tale of caution for microRNA microarray studies

2019

View full text Add to dashboard Cite

show abstract

“…[ 33 , 34 , 35 , 36 , 37 ] Given the critical role of host miRNAs in the regulation of gene expression, antiviral response and immunity, miRNAs are emerging as important markers of responsiveness to vaccination (e.g., influenza and hepatitis B vaccination). [ 38 , 39 , 40 ] While we and others have identified specific gene-expression patterns during measles infection and/or vaccination and identified (gene) transcriptional signatures associated with antibody response after measles vaccination [ 3 , 4 , 5 ], intracellular and/or serum miRNAs have never been explored as factors influencing measles immunity. The results of the current study demonstrate that intracellular B cell-specific miRNA expression is associated with direct or indirect regulation of humoral immunity to measles vaccination.…”

Section: Discussionmentioning

confidence: 99%

Differential miRNA expression in B cells is associated with inter-individual differences in humoral immune response to measles vaccination

et al. 2018

View full text Add to dashboard Cite

BackgroundMicroRNAs are important mediators of post-transcriptional regulation of gene expression through RNA degradation and translational repression, and are emerging biomarkers of immune system activation/response after vaccination.MethodsWe performed Next Generation Sequencing (mRNA-Seq) of intracellular miRNAs in measles virus-stimulated B and CD4+ T cells from high and low antibody responders to measles vaccine. Negative binomial generalized estimating equation (GEE) models were used for miRNA assessment and the DIANA tool was used for gene/target prediction and pathway enrichment analysis.ResultsWe identified a set of B cell-specific miRNAs (e.g., miR-151a-5p, miR-223, miR-29, miR-15a-5p, miR-199a-3p, miR-103a, and miR-15a/16 cluster) and biological processes/pathways, including regulation of adherens junction proteins, Fc-receptor signaling pathway, phosphatidylinositol-mediated signaling pathway, growth factor signaling pathway/pathways, transcriptional regulation, apoptosis and virus-related processes, significantly associated with neutralizing antibody titers after measles vaccination. No CD4+ T cell-specific miRNA expression differences between high and low antibody responders were found.ConclusionOur study demonstrates that miRNA expression directly or indirectly influences humoral immunity to measles vaccination and suggests that B cell-specific miRNAs may serve as useful predictive biomarkers of vaccine humoral immune response.

show abstract

“…We determined the expression levels of miR-21, miR-3200, miR-451, and miR-205 using the predesigned TaqMan MicroRNA assay (Life Technologies, Foster City, CA, USA). We synthesized cDNA from 100ng of total RNA using the TaqMan ® MicroRNA Reverse Transcription kit (Life Technologies) and performed RT-qPCR using the 7900HT Fast Real-Time PCR System (Life Technologies)[ 24 ]. RNU6B or miR-191[ 25 ] was used as an endogenous control to normalize tissue or serum samples[ 26 ], respectively.…”

Section: Methodsmentioning

confidence: 99%

Tissue and Serum miRNA Profile in Locally Advanced Breast Cancer (LABC) in Response to Neo-Adjuvant Chemotherapy (NAC) Treatment

et al. 2016

View full text Add to dashboard Cite

IntroductionMicroRNAs (miRNAs) are small non-coding RNA that plays a vital role in cancer progression. Neo-adjuvant chemotherapy (NAC) has become the standard of care for locally advanced breast cancer. The aim of this study was to evaluate miRNA alterations during NAC using multiple samples of tissue and serum to correlate miRNA expression with clinico-pathological features and patient outcomes.MethodsTissue and serum samples were collected from patients with locally advanced breast cancer undergoing NAC at four time points: time of diagnosis, after the first and fourth cycle of doxorubicin/cyclophosphamide treatment, and after the fourth cycle of docetaxel administration. First, we evaluated the miRNA expression profiles in tissue and correlated expression with clinico-pathological features. Then, a panel of four miRNAs (miR-451, miR-3200, miR-21, and miR-205) in serum samples was further validated using quantitative reverse-transcription polymerase chain reaction (RT-qPCR). The alterations in serum levels of miRNA, associations with clinical and pathological responses, correlation with clinico-pathological features, and survival outcomes were studied using Friedman, Mann-Whitney U, and Spearman, Wilcoxon signed-ranks tests. P≤0.05 was considered statistically significant.ResultsWe analyzed 72 tissue samples and 108 serum samples from 9 patients and 27 patients, respectively. MicroRNA expression profiling of tumor versus normal tissue revealed more than 100 differentially expressed miRNAs. Serum miR-451 levels were significantly decreased during treatment, and higher serum levels were associated with improved clinical and pathological responses and disease-free survival. This is one of the early reports on miR-3200 in response to treatment in breast cancer, as serum levels of miR-3200 found to decline during NAC, and higher serum levels were associated with lower residual breast cancer burden and relapse rates at time of diagnosis.ConclusionVariations in serum miRNA levels during NAC treatment may be therapeutically significant for predicting response and survival outcomes.

show abstract

Increased Serum MicroRNA-155 Level Associated with Nonresponsiveness to Hepatitis B Vaccine

Cited by 13 publications

References 10 publications

The effect of H1N1 vaccination on serum miRNA expression in children: A tale of caution for microRNA microarray studies

The effect of H1N1 vaccination on serum miRNA expression in children: A tale of caution for microRNA microarray studies

Differential miRNA expression in B cells is associated with inter-individual differences in humoral immune response to measles vaccination

Tissue and Serum miRNA Profile in Locally Advanced Breast Cancer (LABC) in Response to Neo-Adjuvant Chemotherapy (NAC) Treatment

Contact Info

Product

Resources

About